Jiangsu Yahong Meditech マネジメント

マネジメント基準チェック /24

Jiangsu Yahong Meditechの CEO はKevin Panで、 Mar2010年に任命され、の在任期間は 14.67年です。は、会社の株式の23.16%を直接所有しており、その価値はCN¥ 990.09M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と2.3年です。

主要情報

Kevin Pan

最高経営責任者

CN¥3.4m

報酬総額

CEO給与比率	n/a
CEO在任期間	14.7yrs
CEOの所有権	23.2%
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	2.3yrs

経営陣の近況

Recent updates

Industry Analysts Just Made A Huge Upgrade To Their Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Revenue Forecasts

Oct 01

CEO（最高経営責任者

Kevin Pan (56 yo)

14.7yrs

在職期間

CN¥3,412,400

報酬

Dr. Kevin Pan is Founder, Chairman and Chief Executive Officer at Asieris Pharmaceuticals Co. Ltd since march 16, 2010.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kevin Pan	Founder	14.7yrs	CN¥3.41m	23.16% CN¥ 990.1m
Mingyuan Yang	Financial Manager	3.9yrs	CN¥1.20m	0.0064% CN¥ 272.3k
Chengfeng Zhuang	Deputy GM & Director	3.9yrs	CN¥2.40m	1.07% CN¥ 45.8m
David Wilson	Senior Vice President of BD	no data	データなし	データなし
Alice Chen	Senior VP of Discovery Biology & Head of Translational Research	3.2yrs	データなし	データなし
Linda Wu	Chief Development Officer	1.8yrs	データなし	データなし
Sophia Cao	SVP & Head of the Women's Health Business Unit	less than a year	データなし	データなし

3.5yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 688176の経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Kevin Pan	Founder	14.7yrs	CN¥3.41m	23.16% CN¥ 990.1m
Mingyuan Yang	Financial Manager	less than a year	CN¥1.20m	0.0064% CN¥ 272.3k
Chengfeng Zhuang	Deputy GM & Director	5.3yrs	CN¥2.40m	1.07% CN¥ 45.8m
Neal Shore	Member of the Advisory Board	less than a year	データなし	データなし
Zhisong He	Member of Clinical Advisory Committee	no data	データなし	データなし
Badrinath Konety	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Bin Huang	Independent Director	3.9yrs	CN¥150.00k	データなし
Bing Hui Zhang	Independent Director	3.9yrs	CN¥150.00k	データなし
Yi Zhong	Chairman of the Supervisory Board	3.9yrs	データなし	データなし
Xianxian Li	Director	less than a year	データなし	データなし
Joseph Liao	Member of the Advisory Board	less than a year	データなし	データなし
Wenning Wang	Independent Director	less than a year	データなし	データなし

2.3yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: 688176の取締役会は経験豊富ではない ( 2.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Jiangsu Yahong Meditech マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Jiangsu Yahong Meditech Co., Ltd., Annual General Meeting, Jun 27, 2024

Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit

Asieris Pharmaceuticals Appoints Dr. Linda Wu as Chief Development Officer

Less than half of directors are independent

Asieris Pharmaceuticals Appoints Dr. Badrinath Konety to Scientific Advisory Board

Recent updates

Consensus revenue estimates increase by 10%

Jiangsu Yahong Meditech Co., Ltd Receives Marketing Approval by the National Medical Products Administration for Hexvix in China

Third quarter 2024 earnings released: CN¥0.16 loss per share (vs CN¥0.14 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Industry Analysts Just Made A Huge Upgrade To Their Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Revenue Forecasts

Jiangsu Yahong Meditech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Consensus revenue estimates increase by 43%

Second quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.22 loss in 2Q 2023)

Jiangsu Yahong Meditech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Jiangsu Yahong Meditech Co., Ltd., Annual General Meeting, Jun 27, 2024

New major risk - Revenue and earnings growth

Now 20% undervalued

Photocure ASA Partner Asieris Pharmaceuticals Announces New Drug Application Acceptance for Regulatory Review of Cevira in China

First quarter 2024 earnings released: CN¥0.15 loss per share (vs CN¥0.11 loss in 1Q 2023)

Consensus revenue estimates increase by 12%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Jiangsu Yahong Meditech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN

Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) announces an Equity Buyback for CNY 100 million worth of its shares.

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU

Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit

Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China

Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting

Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Hong Kong Department of Health Approves the Registration Applications for the Uro-G and Uro-V DisposableCystoscopic System

Asieris Pharmaceuticals Confirms Hexvix Phase III Clinical Trial in China Meet Endpoint

Asieris Pharmaceuticals Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Asieris' Progress in MIBC Receives Renewed Attention with Its Inclusion in Asco 2023

Asieris Pharmaceuticals Appoints Dr. Linda Wu as Chief Development Officer

Asieris Pharmaceuticals' Bladder Cancer Diagnostic Drug Hexvix Completes Dosing of First Patient in Real-World Clinical Study

Less than half of directors are independent

Asieris Pharmaceuticals Obtaines IND Approval from US FDA for APL-1401, A New Drug for the Treatment of Moderately-To-Severely Active Ulcerative Colitis

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

Asieris Pharmaceuticals Announces Patient Enroll in Hexvix Phase III Trial in China

Asieris Pharmaceuticals Appoints Dr. Badrinath Konety to Scientific Advisory Board

Asieris Pharmaceuticals Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

Asieris Pharmaceuticals to Present Study Protocol of APL-1202 in Combination with Beigene's Tislelizumab as Neoadjuvant Therapy For Muscle Invasive Bladder Cancer Patients At 2022 ASCO Annual Meeting

Photocure ASA Partner Asieris Pharmaceuticals Announces Approval to Conduct A Phase III Clinical Trial for Hexvix in China

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24